HOME >> BIOLOGY >> NEWS
Columbia University awards 2006 Horwitz Prize to biologist who explained gene transcription

New York, NY October 4, 2006 Columbia University will award the 2006 Louisa Gross Horwitz Prize to structural biologist Roger D. Kornberg, Ph.D., Winzer Professor in Medicine at the Stanford School of Medicine. Dr. Kornberg will be honored for his work revolutionizing our understanding of gene transcription, the first step in transforming the genomic code in the cell into proteins, which run the cell.

It was also announced today that Dr. Kornberg has won the 2006 Nobel Prize in Chemistry.

"Dr. Kornberg's research is fundamental in pointing the way to innovative therapies for cancer, heart disease and other illnesses in which there is disturbance of genetic activity," said Lee Goldman, M.D., executive vice president of Columbia University and dean of the faculties of health sciences and medicine at Columbia University Medical Center. "His work represents exactly the type of scientific activity that we are proud to honor with the Horwitz Prize."

"We are pleased to continue our Horwitz tradition by awarding this year's prize to Roger Kornberg," said David Hirsh, Ph.D., executive vice president for research at Columbia University. "His groundbreaking work has been central to explaining the fundamental basis of gene regulation."

The Louisa Gross Horwitz Prize was established by Columbia University to recognize outstanding contributions to basic research in the fields of biology and biochemistry. Awarded annually since 1967, the prize was named for the mother of Columbia benefactor S. Gross Horwitz. Louisa Gross Horwitz was daughter of Dr. Samuel David Gross, author of "A System of Surgery" and a founder of the American Medical Association. For additional information about the Louisa Gross Horwitz Prize, visit: http://www.cumc.columbia.edu/horwitz.

"I'm pleased to receive this prestigious recognition, and am delighted to share the honor with some of the most distingu
'"/>

Contact: Craig LeMoult
cel2113@columbia.edu
212-305-0820
Columbia University Medical Center
4-Oct-2006


Page: 1 2 3

Related biology news :

1. Columbia University Medical Center awarded $3 million to drive Alzheimers genetics research
2. Columbia scientists determine 3-dimensional structure of cells fuel gauge
3. Columbia University licenses next-generation DNA sequencing technology
4. New bird discovered on unexplored Columbian mountain
5. Columbia University Medical Center receives major new NIH Clinical Science investment funds
6. Columbia University receives $16.9 million NIEHS award to study arsenic in ground water
7. Contaminants linked to sturgeon decline in Columbia river
8. Columbia University Medical Center researchers discover potential mechanism for tumor growth
9. UF, Columbia scientists closer to new cancer detection method
10. Columbia University awards 2005 Horwitz Prize to Israeli structural biologist
11. Columbia wins major grant to examine genetic link to Alzheimers Disease

Post Your Comments:
(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: